Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Axel Cloeckaert, Institut National de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), France

*CORRESPONDENCE Hisham Atan Edinur edinur@usm.my

RECEIVED 09 March 2025 ACCEPTED 11 March 2025 PUBLISHED 25 March 2025

CITATION

Safuan S, Pati S and Edinur HA (2025) Editorial: MicroRNA: the swift development in infectious diseases. *Front. Microbiol.* 16:1590218. doi: 10.3389/fmicb.2025.1590218

COPYRIGHT

© 2025 Safuan, Pati and Edinur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: MicroRNA: the swift development in infectious diseases

Sabreena Safuan¹, Siddhartha Pati² and Hisham Atan Edinur^{1*}

¹School of Health Sciences, Universiti Sains Malaysia, Health Campus, Kota Bharu, Kelantan, Malaysia, ²NatNov Bioscience Private Limited, Balasore, India

KEYWORDS

microRNA, infectious diseases, vector-borne diseases, zoonotic disease, treatments

Editorial on the Research Topic MicroRNA: the swift development in infectious diseases

MicroRNAs (miRNAs) are short, non-protein-coding ribonucleic acid (RNA) molecules that act as post-transcriptional regulators via binding to the 3' untranslated regions (3'-UTRs) of target messenger RNAs (mRNAs) (Ratti et al., 2020). They negatively regulate gene expression, particularly by degrading target mRNAs or inhibiting the translation of proteins. Thousands of them have been well characterized and shown to act on cell growth signaling pathways, differentiation, apoptosis, pathogen-host interactions, stress responses, and immune function (Tribolet et al., 2020; Kimura et al., 2023). The discovery of miRNAs as important players in gene regulation has opened up a new dimension of research in molecular biology, particularly in the study of infectious diseases. Therefore, this Research Topic aims to collect the latest advancements on the impact of miRNAs on pathogen-host interactions and their potential as prognostic biomarkers and therapeutic targets.

During infection, significant changes in miRNA expression can be detected as part of the immune response modulation to protect the host. Pathogens can also exploit the host's miRNA machinery to evade detection, suppresses immune responses, and facilitate colonization within the host. In this Research Topic, Bostanghadiri et al. investigated the association between Fusobacterium nucleatum, a Gram-negative anaerobic bacterium, and miRNA expression levels in colorectal adenocarcinoma and matched adjacent normal tissues. They reported higher levels of F. nucleatum and elevated expression of cytokines (IL-6, IL-17, TNF- α , and TLR-4) in tumor tissues compared to normal tissues. miR-21 and miR-31 gene expression showed significant fold change in cancer vs. normal tissue, with the former miRNA correlated with high concentrations of F. nucleatum. Their findings suggested that miR-21 could be a potential biomarker of colorectal cancer. Wang et al. also discussed the exploitation of host miRNA expression by Echinococcus parasites in the immune evasion process. Their study investigated the immunomodulatory mechanisms of mesenchymal stem cells (MSCs) treated with hydatid antigens isolated from sheep and mice. The functional and expression analyses demonstrated the effects of hydatid antigens on miR-146a and miR-9-5p levels in the extracellular vesicles (EVs) extracted from the MSCs.

miRNAs as prognostic biomarkers and therapeutic targets were also discussed in detail in this Research Topic. Muchtar et al. reported microRNA-3145 as a potential therapeutic tool for hepatitis B virus treatment. miR-3145 inhibits HPV replication by

downregulating hepatitis B virus S antigen and hepatitis B virus X. In a separate study, Jin et al. conducted a meta-analysis to evaluate the value of miRNAs as both prognostic and diagnostic biomarkers in sepsis patients. A total of 55 studies were included in the meta-analysis, with miR-133a-3p showing the highest diagnostic accuracy. Other miRNAs, including miR-146a, miR-21, miR-210, miR-223-3p, and miR-155, could also potentially be used as biomarkers for predicting sepsis mortality. In another review, Venkatesan et al. discussed the potential applications of exosome miRNAs as diagnosis markers of vector-borne diseases. These include for malaria, schistosomiasis, rickettsia, Chagas, and Japanese encephalitis. They also highlighted the lack of plasma exosome research, although plasma-derived exosome miRNAs were shown to be differentially expressed in vector-borne infected hosts.

In conclusion, the articles collected under this Research Topic provide important updates on the role of miRNAs during pathogen colonization and disease pathogenesis. Understanding miRNA biogenesis and the associated machinery in the context of infectious diseases is not only essential for advancing our knowledge but also carries significant potential for the development of novel prognostic biomarkers and therapeutic strategies.

Author contributions

SS: Conceptualization, Writing – original draft, Writing – review & editing. SP: Writing – review & editing. HE:

Conceptualization, Writing - original draft, Writing - review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Conservation Trust Fund for Natural Resources from Ministry of Energy and Natural Resources Malaysia (grant no: 304/PPSK/6150219) led by H. A. Edinur.

Conflict of interest

SP was employed by NatNov Bioscience Private Limited.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Kimura, M., Kothari, S., Gohir, W., Camargo, J. F., and Husain, S. (2023). MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets. *Clin. Microbiol. Rev.* 36:e0001523. doi: 10.1128/cmr.00015-23

Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., et al. (2020). MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools

for cancer therapy: first steps from bench to bedside. *Target Oncol.* 15:261–278. doi: 10.1007/s11523-020-00717-x

Tribolet, L., Ker, E., Cowled, C., Bean, A. G. D., Stewart, C. R., Dearnley, M., et al. (2020). MicroRNA biomarkers for infectious diseases: from basic research to biosensing. *Front. Microbiol.* 11:1197. doi: 10.3389/fmicb.2020.01197